Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucinactant for Respiratory Distress Syndrome in Preterm Neonates (26-32 Weeks)
NCT02636868Phase 2Completed
- Sponsor
- Windtree Therapeutics, Inc.
- Start
- Dec 2015
- Primary completion
- Jul 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
A Phase 2 trial of lucinactant in respiratory distress syndrome (RDS), sponsored by Windtree Therapeutics, Inc.. Started Dec 2015; status: completed.
02
Drugs
lucinactant
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NCT02636868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02636868.